Literature DB >> 30937550

Survivorship Guidance for Patients with Colorectal Cancer.

Jillian Simard1, Suneel Kamath2, Sheetal Kircher3.   

Abstract

OPINION STATEMENT: Effective therapy for treatment of colorectal cancer includes comprehensive and evidence-based therapies that may include a combination of surgery, chemotherapy, targeted therapy, and/or radiation. However, in order to provide patients with the highest quality of care, providers must consider all aspects of survivorship care including: surveillance for recurrence/second primaries, genetic counseling, psychosocial/physical late effects of cancer and its therapies, and preventative lifestyle strategies. Health systems, providers, and researchers need to identify systematic methods of addressing the unique needs of the survivorship population that include multidisciplinary teams including supportive oncology (i.e., psychologists, social workers), specialties (i.e., cardiology), and primary care physicians.

Entities:  

Keywords:  Cancer; Colorectal neoplasms; Diet; Exercise; Genetics; Neoplasms; Recurrence; Survivorship

Year:  2019        PMID: 30937550     DOI: 10.1007/s11864-019-0635-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  78 in total

Review 1.  Models for delivering survivorship care.

Authors:  Kevin C Oeffinger; Mary S McCabe
Journal:  J Clin Oncol       Date:  2006-11-10       Impact factor: 44.544

2.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

3.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Authors:  Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

4.  Occurrence of second cancers in patients treated with radiotherapy for rectal cancer.

Authors:  Helgi Birgisson; Lars Påhlman; Ulf Gunnarsson; Bengt Glimelius
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  Quality of life in long term survivors of colorectal cancer.

Authors:  Scott D Ramsey; Kristin Berry; Carol Moinpour; Antoinette Giedzinska; M Robyn Andersen
Journal:  Am J Gastroenterol       Date:  2002-05       Impact factor: 10.864

6.  Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

Authors:  James J Dignam; Blase N Polite; Greg Yothers; Peter Raich; Linda Colangelo; Michael J O'Connell; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

7.  A population-based analysis of second primary cancers after irradiation for rectal cancer.

Authors:  Wayne S Kendal; Garth Nicholas
Journal:  Am J Clin Oncol       Date:  2007-08       Impact factor: 2.339

8.  Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer.

Authors:  Kimmie Ng; Jeffrey A Meyerhardt; Kana Wu; Diane Feskanich; Bruce W Hollis; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 9.  Factors affecting cancer survivors' employment and work ability.

Authors:  T Taskila; M L Lindbohm
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

10.  Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.

Authors:  Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Frank B Hu; Robert J Mayer; Heidi Nelson; Renaud Whittom; Alexander Hantel; James Thomas; Charles S Fuchs
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

View more
  6 in total

1.  Prognostic impact of the preoperatory neutrophil/lymphocyte index on early surgical complications of patients with colorectal cancer.

Authors:  Ignacio Escobar-Munguía; Ricardo Berea-Baltierra; Ángel Morales-González; Eduardo Madrigal-Santillán; Liliana Anguiano-Robledo; José A Morales-González
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Upregulated long intergenic non-protein coding RNA 1094 (LINC01094) is linked to poor prognosis and alteration of cell function in colorectal cancer.

Authors:  Guangliang Zhang; Yingjie Gao; Zhen Yu; Hui Su
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Active Enhancer Assessment by H3K27ac ChIP-seq Reveals Claudin-1 as a Biomarker for Radiation Resistance in Colorectal Cancer.

Authors:  Zu-Xuan Chen; He-Qing Huang; Jia-Ying Wen; Li-Sha Qin; Yao-Dong Song; Ye-Ying Fang; Da-Tong Zeng; Wei-Jian Huang; Xin-Gan Qin; Ting-Qing Gan; Jie Luo; Jian-Jun Li
Journal:  Dose Response       Date:  2021-12-08       Impact factor: 2.658

Review 4.  Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.

Authors:  Alfred Buhagiar; Elisa Seria; Miriana Borg; Joseph Borg; Duncan Ayers
Journal:  Cancer Drug Resist       Date:  2021-10-26

5.  Healthcare professionals' perspectives of barriers and facilitators in implementing physical activity programmes delivered to cancer survivors in a shared-care model: a qualitative study.

Authors:  Charlotte IJsbrandy; Wim H van Harten; Winald R Gerritsen; Rosella P M G Hermens; Petronella B Ottevanger
Journal:  Support Care Cancer       Date:  2019-12-02       Impact factor: 3.603

6.  Clinical significance of microRNA-1180-3p for colorectal cancer and effect of its alteration on cell function.

Authors:  Chunlei Li; Wei Jin; Dewei Zhang; Shoujin Tian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.